Plus Therapeutics, Inc. (PSTV) Stock Forecast
Data as of Aug 1, 2026Healthcare · Current price $3.86 (+5.82%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
Top Analysts Covering PSTV
PSTV vs Sector & Market
| Metric | PSTV | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.33 | 2.25 | 2.42 |
| Analyst Count | 3 | 8 | 19 |
| Target Upside | +547.2% | +16315.5% | +17.1% |
| P/E Ratio | -0.83 | 3.01 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $5M | $6M | $7M | 4 |
| 2027-12-31 | $16M | $21M | $26M | 4 |
| 2028-12-31 | $30M | $48M | $65M | 4 |
| 2029-12-31 | $84M | $134M | $183M | 3 |
| 2030-12-31 | $117M | $186M | $255M | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-3.54 | $-3.45 | $-3.36 | 3 |
| 2027-12-31 | $-2.21 | $-2.13 | $-2.05 | 3 |
| 2028-12-31 | $-0.67 | $-0.46 | $-0.24 | 4 |
| 2029-12-31 | $2.32 | $4.47 | $6.61 | 2 |
| 2030-12-31 | $3.88 | $7.48 | $11.06 | 2 |
Frequently Asked Questions
What is the analyst consensus for PSTV?
The consensus among 3 analysts covering Plus Therapeutics, Inc. (PSTV) is Buy with an average price target of $25.00.
What is the highest price target for PSTV?
The highest price target for PSTV is $50.00, set by Sean Lee at H.C. Wainwright on 2025-11-26.
What is the lowest price target for PSTV?
The lowest price target for PSTV is $25.00, set by Sean Lee at H.C. Wainwright on 2026-01-23.
How many analysts cover PSTV?
3 analysts have issued ratings for Plus Therapeutics, Inc. in the past 12 months.
Is PSTV a buy or sell right now?
Based on 3 analyst ratings, PSTV has a consensus rating of Buy (2.33/5) with a +547.2% upside to the consensus target of $25.00.
What are the earnings estimates for PSTV?
Analysts estimate PSTV will report EPS of $-3.45 for the period ending 2026-12-31, with revenue estimated at $6M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.